Sanofi (NASDAQ:SNY) Shares Sold by Sage Rhino Capital LLC

Sage Rhino Capital LLC cut its position in Sanofi (NASDAQ:SNY) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,206 shares of the company’s stock after selling 516 shares during the quarter. Sage Rhino Capital LLC’s holdings in Sanofi were worth $408,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Rise Advisors LLC grew its stake in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares in the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at $27,000. Venturi Wealth Management LLC grew its stake in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares in the last quarter. CNB Bank acquired a new position in Sanofi during the 3rd quarter worth $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA grew its stake in Sanofi by 115.6% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock worth $37,000 after purchasing an additional 400 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 0.3 %

Shares of NASDAQ:SNY traded up $0.14 on Tuesday, hitting $49.23. 3,182,534 shares of the company’s stock were exchanged, compared to its average volume of 2,021,368. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.93. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The company has a market capitalization of $124.53 billion, a PE ratio of 24.74, a P/E/G ratio of 1.48 and a beta of 0.61. The firm’s 50-day moving average is $47.82 and its 200 day moving average is $48.25.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sell-side analysts predict that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s payout ratio is presently 69.35%.

Analysts Set New Price Targets

Several research analysts recently commented on SNY shares. Morgan Stanley started coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.